Compare BKU & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKU | EWTX |
|---|---|---|
| Founded | 2009 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 2010 | 2021 |
| Metric | BKU | EWTX |
|---|---|---|
| Price | $43.15 | $28.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $52.18 | $37.38 |
| AVG Volume (30 Days) | 734.5K | ★ 735.0K |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 14.61 | N/A |
| EPS | ★ 3.53 | N/A |
| Revenue | ★ $21,732,000.00 | N/A |
| Revenue This Year | $16.55 | N/A |
| Revenue Next Year | $4.77 | N/A |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | ★ 7.45 | N/A |
| 52 Week Low | $28.21 | $10.60 |
| 52 Week High | $52.11 | $31.82 |
| Indicator | BKU | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.87 | 48.13 |
| Support Level | $37.36 | $28.56 |
| Resistance Level | $46.92 | $31.12 |
| Average True Range (ATR) | 1.26 | 1.46 |
| MACD | -0.24 | -0.07 |
| Stochastic Oscillator | 22.42 | 44.71 |
BankUnited Inc is a bank holding company with one wholly owned subsidiary, BankUnited. The bank provides a full range of banking services through banking centers located throughout Florida, as well as New York City. The company is a commercially focused regional bank focusing on small and middle-market businesses, but also provides certain commercial lending and deposit products on a national platform. The Bank offers a comprehensive suite of commercial lending and deposit products through an Atlanta office focused on the Southeast region, certain commercial lending and deposit products through national platforms and certain consumer deposit products through an online channel.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.